Sign In
Buy LLY
$1,192.80
+22.94 (+1.96%)
At Close: Aug 06, 2026
Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment
01:14pm, Thursday, 07'th Aug 2025
Eli Lilly delivered strong Q2 results, raising full-year guidance, but shares plunged over 15% due to underwhelming Orforglipron weight loss data. Tirzepatide's explosive growth cements Lilly's domina
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
12:35pm, Thursday, 07'th Aug 2025
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript
12:28pm, Thursday, 07'th Aug 2025
Eli Lilly and Company (NYSE:LLY ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel M. Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research L
Jobless Claims Increased More Than Expected
12:20pm, Thursday, 07'th Aug 2025
Another full morning of market data to go through today, which will help articulate where we are in several accounts of the massive U.S. economy. Pre-market futures were at peak highs just ahead of ne
Top Stock Movers Now: DoorDash, Fortinet, Eli Lilly, and More
12:15pm, Thursday, 07'th Aug 2025
U.S. equities were mixed at midday as the market continued to focus on earnings, and new U.S. tariffs kicked in. The Nasdaq was up, while the Dow Jones Industrial Average and S&P 500 fell.
Jobless Claims, Q2 Productivity, Q2 Earnings All Higher
11:36am, Thursday, 07'th Aug 2025
Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Lilly's New Weight-Loss Pill Underperforms in Study
11:32am, Thursday, 07'th Aug 2025
Eli Lilly & Co.'s new weight-loss pill had lower weight loss and higher rates of nausea and vomiting than anticipated in a study, according to the company. That news sent the stock plunging Thursday m
Eli Lilly shares drop despite Q2 beat
11:19am, Thursday, 07'th Aug 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest earnings from drugmaker Eli Lilly.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
10:45am, Thursday, 07'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Lilly (LLY) Reports Q2 Earnings: What Key Metrics Have to Say
10:31am, Thursday, 07'th Aug 2025
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street esti
Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
10:15am, Thursday, 07'th Aug 2025
Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical firm reported disappointing results from a late-stage study of its experimental obesity pill. The news offset Lilly's strong quarterly
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
09:55am, Thursday, 07'th Aug 2025
On Thursday, Eli Lilly and Co.'s LLY weight loss rival Novo Nordisk A/S NVO, along with smaller firms, Terns Pharmaceuticals, Inc. TERN, Viking Therapeutics Inc. VKTX, and Structure Therapeutics Inc.
Eli Lilly shares tumble on disappointing weight loss drug trial data
09:40am, Thursday, 07'th Aug 2025
Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for the company's oral weight loss drug orforglipron drew focus from strong second quart
"Disappointment Overall" for LLY Earnings, ABNB Shows Travel Weakness
09:30am, Thursday, 07'th Aug 2025
Eli Lilly's (LLY) earnings beat wasn't enough draw investors in. The bigger focus was on the company's weight loss pill that showed "disappointing" results.
Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates
08:55am, Thursday, 07'th Aug 2025
Eli Lilly (LLY) came out with quarterly earnings of $6.31 per share, beating the Zacks Consensus Estimate of $5.61 per share. This compares to earnings of $3.92 per share a year ago.
